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Background/aim: Defective vascularization may be important in thyroid nodular disease. In this study, we aimed to investigate serum
vascular endothelial growth factor (VEGF) levels in dyslipidemic patients with thyroid nodules, as well as the effects of statin therapy.
Materials and methods: The study included 37 dyslipidemic patients with thyroid nodules and 32 dyslipidemic patients without thyroid
nodules. Anthropometry, serum VEGF levels, biochemical parameters, thyroid-stimulating hormone (TSH), free triiodothyronine
(fT3) and free thyroxine (fT4) levels, and thyroid sonography were determined before and after 6 months of statin therapy.
Results: Patients with and without thyroid nodules had similar metabolic parameters. Serum VEGF levels did not differ between the
groups. In patients with nodules, VEGF levels remained unchanged (P = 0.931) after statin therapy. However, serum VEGF levels were
lowered by statin treatment in patients without nodules (P = 0.030). Statin therapy resulted in a decrease in the dominant thyroid nodule
volume. The changes in thyroid volume and dominant thyroid nodule volume were not correlated with changes in VEGF, body mass
index, total cholesterol, low-density lipoprotein cholesterol, or homeostatic model assessment of insulin resistance (HOMA-IR).
Conclusion: Although statin treatment decreases serum VEGF levels in dyslipidemic patients without thyroid nodules, it has no
lowering effect on serum VEGF levels in patients with thyroid nodules. The decrease in thyroid nodule volume with statin treatment
was associated with neither metabolic parameters nor serum VEGF levels.
Key words: Statin, vascular endothelial growth factor, thyroid nodule, dyslipidemia

1. Introduction
Thyroid hormones appear to serve as a general metabolic
controller coordinating many metabolic processes;
thus, the association of metabolic syndrome and its
components with thyroid function and nodule formation
is an intriguing area of research in thyroidology (1–3).
In a number of studies, increased thyroid volume and
nodularity were shown to be associated with metabolic
syndrome parameters, including dyslipidemia (1–3).
Vascularization is an important feature of tumor
growth and might promote the progression of thyroid
nodules. Recently, Wang et al. demonstrated that insulin
resistance and hyperglycemia resulted in increased
intranodular vascularization, which might contribute
to the growth and progression of nodules (4). Vascular

endothelial growth factor (VEGF) is a critical regulator
of angiogenesis and is involved in tumor development.
VEGF expression was found to be associated with lymph
node metastasis, advanced tumor stage, and increased
recurrence risk in malignant thyroid cancers (5–7).
Research investigating the role of VEGF in benign thyroid
disorders yielded controversial results. In vitro and animal
studies have revealed the presence of VEGF in follicular
cells from normal thyroids and VEGF is upregulated in
benign thyroid disorders (8,9). Other studies found no or
weak expression of VEGF in benign nodular goiter (10,11).
Malkomes et al. recently demonstrated coexpression
of VEGF and its receptors in normal thyrocytes and in
benign thyroid diseases, measuring higher concentrations
of VEGF protein in nodular tissue (12). Itoh et al. found
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that there was no VEGF expression in normal thyroid
tissue, slightly positive expression in benign follicular
tumors, and increased expression in differentiated thyroid
cancers; they suggested that VEGF expression reflects
both transformation and differentiation states of thyroid
tumors (13).
Statins are cholesterol-lowering agents that prevent
reduction of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) to mevalonate by inhibiting HMG-CoA
reductase. Beyond lipid-lowering effects, they have
immunomodulatory, antiinflammatory, and antioxidant
activity unrelated to the effects on lipid metabolism
(14–17). Furthermore, statins have a potential role in
angiogenesis, a process intimately linked with angiogenic
growth factors acting on the endothelium. Statins were
demonstrated to reduce VEGF expression or serum
VEGF levels in a variety of diseases with increased VEGF
expression such as type 2 diabetes, coronary artery disease,
dyslipidemia, and lung cancer, and their use has been
encouraged for their pleiotropic and antiangiogenic effects
(17–19).
Moreover, the antigoitrogenic effects of statins have
been demonstrated in a number of in vitro studies, which
have revealed that statins induce apoptosis in thyroid cells
and decrease thyroid hypertrophy and hyperplasia induced
by goitrogenic agents (20–22). The antigoitrogenic effect
of statins was further evaluated by a retrospective analysis
confirming that treatment with statins was associated with
smaller thyroid size and significantly lower prevalence,
number, and volume of thyroid nodules (23).
Dyslipidemia is shown to be associated with increased
thyroid volume and thyroid nodules. Statins have
contingent beneficial effects on thyroid nodules and a
lowering effect on VEGF levels in a variety of VEGFincreased conditions. Therefore, we designed this study to
evaluate serum VEGF levels in dyslipidemic patients with
and without thyroid nodules and prospectively evaluate
the effect of statin therapy on thyroid nodules and serum
VEGF levels.
2. Materials and methods
We enrolled 37 dyslipidemic patients with thyroid
nodules and 32 dyslipidemic patients without thyroid
nodules who were intended to receive statin treatment
according to Adult Treatment Panel III (ATP-III) criteria.
All the patients were evaluated prior to statin therapy
and after 6 months of statin therapy. Other medications
remained unchanged during the study period.
Thyroid ultrasonographic evaluation, detailed physical
examination including anthropometric measurements
and blood pressure, analysis of lipid parameters, fasting
blood glucose and insulin, thyroid-stimulating hormone
(TSH), free triiodothyronine (fT3) and free thyroxine

(fT4) levels, thyroglobulin, antithyroid peroxidase
antibody (anti-TPO), antithyroglobulin antibody (antiTG), and VEGF levels were obtained before and after
therapy. Body mass index (BMI) was calculated according
to the following formula: weight in kilograms/square of
height in meters. Waist circumference was measured at the
level of the umbilicus; hip circumference was measured at
the largest point. Waist to hip ratio (WHR) was calculated.
Patients were evaluated at 2-month intervals to optimize
the low-density lipoprotein cholesterol (LDL-C) goals,
and drug dosages were titrated accordingly. After 6
months of treatment with statin, subjects were asked to
return all empty blister packs to determine the individual’s
compliance. Patients with malignant disease, renal or
hepatic disease, acute or chronic infection, rheumatologic
disorders, and any medication affecting thyroid function
tests were excluded from the study, as well as patients who
did not complete the 6-month course of therapy due to
side effects or lack of follow-up. The study protocol was
approved by the university’s local ethics committee and was
performed in accordance with the Declaration of Helsinki.
All participants provided written informed consent.
2.1. Ultrasonographic evaluation
Ultrasonographic thyroid evaluations were performed
by the same skilled sonographer using a Doppler
ultrasonographic scanner (LOGIQ 3, General Electric,
Solingen, Germany) equipped with a 10-MHz linear
transducer. Thyroid volume, number of thyroid nodules,
sum of thyroid nodule volumes, dominant nodule volume,
and characteristic sonographic features of each nodule
were recorded. The reproducibility of ultrasonographic
measurements was tested in a control group consisting of
10 healthy volunteers with measurements performed by
the same operator 3 times at 10-min intervals and analyzed
using analysis of variance. The coefficient of variation was
4.1%.
The volumes of thyroid glands and thyroid nodules
were calculated with the standard formula for an ellipsoid
volume, and the thyroid volume was the sum of all thyroid
lobes’ volumes. In cases of multinodularity, sonographic
features of up to 4 nodules in each lobe were evaluated.
Sonographic characteristics of nodules were evaluated in
5 categories: (a) structure: solid, cystic, or mix type; (b)
echogenicity: isoechoic, hypoechoic, or hyperechoic;
(c) vascularity: internal, peripheral, both, or none; (d)
border shape: regular or irregular; (e) halo: hypoechoic,
hyperechoic, or none. Differences in these characteristics
for each nodule after 6 months of therapy were recorded.
2.2. Laboratory analysis
Blood samples were obtained after an overnight fast in
the early morning between 0800 and 1000 hours. The
sera of blood samples centrifuged at 4000 rpm for 20
min were stored at –80 °C until assayed. Triglycerides
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(TG), total cholesterol (TC), LDL-C, and high-density
lipoprotein cholesterol (HDL-C) were measured using
enzymatic calorimetric kits with intra- and interassay
coefficients of variation (CVs) of <10% (Roche Diagnostics
GmbH, Mannheim, Germany). Thyroid hormone
levels including TSH, fT3, and fT4 were measured by
electrochemiluminescence immunoassay method (Roche
Diagnostics GmbH, Mannheim, Germany). Fasting
plasma glucose (FPG) was measured by the glucose
oxidase method (Olympus AU 2700, Beckman Coulter
Inc., Brea, CA, USA). Insulin levels were measured with an
immunoradiometric assay (IRMA) (Immunotech, Prague,
Czech Republic). Serum VEGF levels were determined by
the enzyme-linked immunosorbent assay method using a
commercially available kit (R&D Systems, Minneapolis,
MN, USA). The average intra- and interassay CVs for
VEGF were ≤6.7% and ≤8.8%, respectively. Homeostatic
model assessment for insulin resistance (HOMA-IR) was
calculated according to the following formula: glucose
(mg/dL) × insulin ([µIU/mL])/405.
2.3. Statistical analysis
Statistical analyses were carried out using SPSS 17.0 (SPSS
Inc., Chicago, IL, USA). Differences between means were
analyzed by Wilcoxon rank test and paired sample t-test
according to the normality of distribution determined
by Kolmogorov–Smirnov test. Correlation analysis was
performed with Spearman correlation rank test. The
results are given as mean ± standard deviation or median
(range) when appropriate, and P < 0.05 was accepted as
statistically significant. Changes in the thyroid volume,
dominant thyroid nodule volume, and sum of all nodule
volumes were correlated with changes in BMI, VEGF, TC,
LDL-C, and HOMA-IR by generalized estimated equation
(GEE) analysis.
3. Results
A total of 69 patients (21 males, 48 females) with dyslipidemia
(mean age: 55.2 ± 8.6 years) were included in the study; 43
patients were treated with atorvastatin and the remaining
26 patients were treated with rosuvastatin. In patients
with thyroid nodules, 26 patients were on atorvastatin
treatment and 11 patients were on rosuvastatin treatment.
The average dosages for atorvastatin and rosuvastatin were
13.5 ± 4.8 mg and 10.9 ± 3.0 mg, respectively. In patients
without thyroid nodules, 17 patients were on atorvastatin
therapy and 15 patients were on rosuvastatin treatment;
the average dosages were 12.4 ± 4.4 mg and 11.3 ± 3.5 mg,
respectively. Atorvastatin and rosuvastatin dosages were
similar in patients with and without thyroid nodules (13.5
± 4.8 vs. 12.4 ± 4.4 mg, P > 0.05 for atorvastatin; 10.9 ±
3 vs. 11.3 ± 3.5 mg, P > 0.05 for rosuvastatin). Patients
with and without thyroid nodules had similar metabolic
parameters and serum VEGF levels (Table 1). Additionally,
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incidence of type 2 diabetes and hypertension was similar
among the groups along with medications taken, including
antihypertensive and antidiabetic drugs (Table 2). Thyroid
volume and dominant thyroid nodule volume were similar
in patients with and without diabetes (13.2 ± 6.2 vs. 11.4
± 8.2 mL, P = 0.329 and 0.68 ± 1.2 vs. 0.58 ± 1.1 mL, P
= 0.821, respectively) and in patients with and without
hypertension (14.3 ± 7.9 vs. 11.2 ± 6.1 mL, P = 0.09 and
0.63 ± 1.1 vs. 0.63 ± 1.4 mL, P = 0.998, respectively) .
Clinical and laboratory characteristics of the study
patients without and with thyroid nodules at baseline and
at the end of 6 months of therapy are shown in Tables
3 and 4, respectively. Anthropometric measurements,
systolic and diastolic blood pressures, thyroid function
tests, thyroid autoantibody levels, and glucose metabolism
parameters remained unchanged after therapy. Median
thyroglobulin level in all patients was 8.11 (0–186) ng/mL
and its level was unchanged during the study period (8.33
[0–114] ng/mL) (P = 0.626). As expected, TC, LDL-C,
and triglyceride levels decreased significantly after statin
therapy. Serum VEGF levels did not change after statin
treatment in patients with thyroid nodules (517.6 ± 231.1
vs. 521.0 ± 253.6 pg/mL, P = 0.931). Statin treatment
resulted in a decrease in serum VEGF levels in patients
without nodules (556.9 ± 288.2 vs. 508.7 ± 256.9 pg/mL, P
= 0.030) (Table 3).
Treatment with statin for 6 months caused a significant
decrease in the mean dominant thyroid nodule volume (P
= 0.013) (Table 4). No difference was observed in thyroid
volume before and after statin treatment. Sonographic
characteristics of the evaluated nodules including
structure, echogenicity, vascularity, border shape, and halo
presence did not differ before and after therapy. Doppler
ultrasonographic evaluation revealed no change in the
vascularity of thyroid nodules.
Correlation of changes in the thyroid volume, dominant
thyroid nodule volume, and sum of thyroid nodule volumes
with changes in BMI, VEGF, TC, LDL-C, and HOMA-IR
did not show any associations. Comparison of the changes
in the studied parameters was similar between diabetic
and nondiabetic patients as well as in hypertensive and
normotensive patients.
4. Discussion
The association of metabolic syndrome components and
thyroid disorders is of clinical interest. It has been shown
that serum levels of TSH are higher in obese patients than
in healthy controls, supporting the hypothesis that the axis
involving the hypothalamus, the pituitary, the thyroid, and
the adipose tissue is somehow disrupted (24–27). Insulin
is a thyroid growth factor that stimulates proliferation
of thyroid cells in culture, and it has been shown that
insulin resistance yields increased thyroid volume and
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Table 1. Metabolic parameters of patients with and without thyroid nodules.

Age (years)

Nodule (–)
n = 32

Nodule (+)
n = 37

P

53.2 ± 9.6

56.8 ± 7.3

0.736

Sex (male/female)

13/19

9/28

0.139

BMI (kg/m2)

30.2 ± 4.5

30.9 ± 4.5

0.489

WHR

0.90 ± 0.07

0.92 ± 0.08

0.219

SBP (mmHg)

132.4 ± 18.9

132.0 ± 23.7

0.932

DBP (mmHg)

82.6 ± 12.3

84.1 ± 18.9

0.712

TSH (µIU/mL)

3.01 ± 2.61

2.35 ± 1.15

0.090

Total cholesterol (mg/dL)

240.9 ± 40.5

236.4 ± 33.2

0.612

Triglyceride (mg/dL)

145.6 ± 67.5

153.6 ± 53.9

0.586

LDL-C (mg/dL)

159.1 ± 38.9

155.8 ± 22.4

0.655

HDL-C (mg/dL)

53.2 ± 14.2

53.0 ± 16.0

0.958

FPG (mg/dL)

114.7 ± 30.1

111.6 ± 34.7

0.698

Insulin (µIU/mL)

13.3 ± 6.7

11.2 ± 5.5

0.146

HOMA-IR

3.8 ± 2.4

3.1 ± 1.7

0.148

VEGF (pg/mL)

562.9 ± 291.0

513.9 ± 229.1

0.436

Data are expressed as mean ± SD.
BMI: Body mass index, WHR: waist to hip ratio, SBP: systolic blood pressure, DBP: diastolic
blood pressure, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein
cholesterol, FPG: fasting plasma glucose, HOMA-IR: homeostatic model assessment for insulin
resistance, VEGF: vascular endothelial growth factor.
Table 2. Characteristics of patients with and without thyroid nodules.
Nodule (–)
n = 32

Nodule (+)
n = 37

P

Diabetes, % (+ / –)

71.1 (23 / 9)

52.3 (19 / 18)

0.091

Hypertension, % (+ / –)

31.4 (10 / 22)

48.1 (18 / 19)

0.219

Smoking, % (+ / –)

25.1 (8 / 24)

16.2 (6 / 31)

0.601

ARB, % (+ / –)

18.8 (6 / 26)

18.9 (7 / 30)

0.986

ACE inh, % (+ / –)

12.5 (4 / 28)

21.7 (8 / 29)

0.319

Beta blocker, % (+ / –)

6.2 (2 / 30)

13.5 (5 / 32)

0.310

OAD, % (within diabetics)

60.9 (14 / 23)

6.2 (12 / 19)

0.612

Insulin, % (within diabetics)

30.4 (7 / 23)

36.8 (7 / 19)

0.586

ARB: Angiotensin receptor blocker, ACE inh: angiotensin-converting enzyme inhibitor, OAD:
oral antidiabetic drugs.

nodularity in euthyroid women (1). Moreover, it has also
been demonstrated that thyroid nodularity and thyroid
volume were increased in metabolic syndrome where all
the components including dyslipidemia were significantly
associated with increased thyroid volume and thyroid
nodularity (2,3). In our cohort of dyslipidemic patients,
we aimed to evaluate the effect of statin treatment and
correction of dyslipidemia on thyroid nodules, thyroid

volume, and serum VEGF levels. We found that serum
VEGF levels were similar in dyslipidemic patients with
and without thyroid nodules. Although statin treatment
for 6 months resulted in a decrease in serum VEGF levels
in patients without thyroid nodules, no difference in
serum VEGF levels was observed in patients with thyroid
nodules. The dominant nodule volume decreased after
statin therapy.
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Table 3. Clinical and biochemical features of patients without thyroid nodules at baseline and
at 6th month of therapy.
Baseline
n = 32
Age (years)

6th month
n = 32

P

55.2 ± 8.6

Sex (male/female)

12 / 20

BMI (kg/m2)

30.5 ± 4.5

30.3 ± 4.6

0.896

WHR

0.91 ± 0.08

0.90 ± 0.09

0.189

SBP (mmHg)

131.7 ± 19.7

131.5 ± 24.8

0.850

DBP (mmHg)

82.2 ± 12.2

79.9 ± 10.1

0.287

TSH (µIU/mL)

3.03 ± 2.57

2.52 ± 1.43

0.269

fT3 (pmol/L)

4.81 ± 0.79

4.79 ± 0.85

0.829

fT4 (pmol/L)

15.68 ± 1.89

16.46 ± 2.92

0.181

Anti-TPO (IU/mL)

25 (5–1000)

27 (5–1000)

0.750

Anti-TG (IU/mL)

20 (20–19,557)

20 (20–27,408)

0.187

Total cholesterol (mg/dL)

240.7 ± 40.2

163.1 ± 29.6

<0.001

Triglyceride (mg/dL)

145.7 ± 66.5

126.8 ± 48.0

<0.001

LDL-C (mg/dL)

158.5 ± 38.4

91.7 ± 23.5

<0.001

HDL-C (mg/dL)

53.3 ± 14.0

50.5 ± 15.9

0.040

FPG (mg/dL)

113.9 ± 29.5

116.5 ± 34.5

0.552

Insulin (µIU/mL)

13.2 ± 6.7

13.5 ± 8.5

0.799

HOMA-IR

3.4 ± 2.1

3.7 ± 2.5

0.113

VEGF (pg/mL)

556.9 ± 288.2

508.7 ± 256.9

0.030

Thyroid volume (mL)

12.40 ± 7.00

12.43 ± 7.33

0.854

Data are expressed as mean ± SD or median (range) as appropriate.
BMI: Body mass index, WHR: waist to hip ratio, SBP: systolic blood pressure, DBP: diastolic
blood pressure, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein
cholesterol, FPG: fasting plasma glucose, HOMA-IR: homeostasis model assessment for insulin
resistance, VEGF: vascular endothelial growth factor.

Studies have been done evaluating the effect of statins
on the thyroid. In vitro studies have confirmed the
apoptotic effects of statins on proliferating thyroid cells,
as well as differentiated and anaplastic thyroid cancer cells
(21,22,28). In addition, it has also been demonstrated
that administration of lovastatin to rats inhibited thyroid
hypertrophy and hyperplasia induced by goitrogenic
agents (22). Although positive effects of statins on thyroid
tissue have been demonstrated by a number of authors,
including us, it must also be proven in the clinical arena.
Capelli et al. carried out a study where they demonstrated
that therapy with statins for at least 5 years was associated
with significantly lower prevalence, number, and volume of
thyroid nodules and smaller thyroid size (24). Capelli et al.
found that although their patients were on statin therapy
for 5 years, the duration of treatment was not related to
statin’s effects on the thyroid gland, and thus they could
not draw a conclusion on shorter periods of treatment.
They evaluated the use of concomitant drugs that may
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potentially affect the thyroid gland, such as ACE inhibitors
and beta blockers; however, there was no evaluation of
insulin resistance, hyperglycemia, obesity, or hypertension.
Chon et al. also conducted a similar study where they
evaluated statin’s effect on thyroid nodules in patients with
type 2 diabetes and demonstrated a decrease in nodule
prevalence with statin treatment for at least 5 years, but
their findings were less pronounced than the findings of
Capelli et al. They suggested that this discrepancy could
be explained by higher insulin resistance in their patients
(28). Both studies evaluated the incidence of nodules
under statin treatment. In our study, we evaluated the
possible effect of statin treatment on existing nodules and
found a decrease in dominant thyroid nodule volume even
after 6 months of statin treatment; however, there was
no change in thyroid volume. A number of confounding
factors may influence this finding, such as the relative
iodine deficiency in our study population, as Chon et al.
explained. However, the most reasonable explanation for
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Table 4. Clinical and biochemical features of patients with thyroid nodules at baseline and at
6th month of therapy.
Baseline
n = 37
Age (years)

56.6 ± 7.4

Sex (male/female)

9 / 28

6th month
n = 37

P

BMI (kg/m )

30.7 ± 4.5

30.5 ± 3.9

0.395

WHR

0.91 ± 0.08

0.91 ± 0.07

0.821

SBP (mmHg)

131.7 ± 24.0

131.8 ± 29.6

0.585

DBP (mmHg)

84.1 ± 18.9

82.6 ± 13.7

0.993

TSH (µIU/mL)

1.96 ± 1.17

2.03 ± 1.06

0.733

fT3 (pmol/L)

4.65 ± 0.68

4.81 ± 0.68

0.353

fT4 (pmol/L)

15.70 ± 1.93

15.72 ± 2.20

0.896

Anti-TPO (IU/mL)

21 (7–1000)

25.5 (7–1000)

0.935

Anti-TG (IU/mL)

20 (20–143)

20 (20–189)

0.310

Total cholesterol (mg/dL)

237.1 ± 33.5

176.2 ± 36.0

<0.001

Triglyceride (mg/dL)

151.3 ± 56.0

119.5 ± 43.8

<0.001

LDL-C (mg/dL)

156.6 ± 22.0

100.8 ± 28.8

<0.001

HDL-C (mg/dL)

53.4 ± 16.7

53.9 ± 15.8

0.555

FPG (mg/dL)

111.3 ± 35.0

110.9 ± 26.7

0.735

Insulin (µIU/mL)

11.0 ± 5.6

13.2 ± 9.2

0.140

HOMA-IR

3.0 ± 1.7

3.6 ± 2.2

0.086

VEGF (pg/mL)

517.6 ± 231.1

521.0 ± 253.6

0.931

Thyroid volume (mL)

14.12 ± 7.21

14.3 ± 7.52

0.884

Dominant nodule volume (mL)

0.16 (0.01–6.09)

0.14 (0.01–6.44)

0.013

Total nodule volume (mL)

0.21 (0.03–6.09)

0.20 (0.01–7.96)

0.039

2

Data are expressed as mean ± SD or median (range) as appropriate.
BMI: Body mass index, WHR: waist to hip ratio, SBP: systolic blood pressure, DBP: diastolic
blood pressure, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein
cholesterol, FPG: fasting plasma glucose, HOMA-IR: homeostasis model assessment for insulin
resistance, VEGF: vascular endothelial growth factor.

this finding is the metabolic disease background of the
patients. In our dyslipidemic patient population including
diabetic and hypertensive patients as well as nondiabetic
and normotensive patients, statin treatment ameliorating
one of the metabolic parameters may be effective in
decreasing thyroid nodule volume. However, GEE analysis
failed to show an association between change in lipid levels
and thyroid nodule volume, suggesting a complicated
cascade other than correction of dyslipidemia.
Capelli et al. and Chon et al. retrospectively evaluated
the prevalence of thyroid nodules in statin-treated
patients and compared the results with those of statinnaïve controls. Due to the nature of their study designs,
there is no potential explanation for how statin resulted
in a decrease in thyroid nodularity. Vascularization is an
important feature of tumor growth that might contribute

to the growth and progression of thyroid nodules and
VEGF is one of the most powerful angiogenesis stimulators
(4,29). High expression of VEGF in thyroid cancer was
found to be correlated with advanced tumor stage, lymph
node metastasis, and increased risk of recurrence (5–7).
Therefore, VEGF inhibitors are approved for the treatment
of advanced thyroid cancers (30). VEGF has also been
found to be upregulated in the pathogenesis of benign
thyroid disorders (9). Increased expression of VEGF and
its receptors in nodular tissue of uninodular and recurrent
goiter as well as in the entire tissue of multinodular goiter
has been demonstrated (29). Furthermore, tyrosine kinase
inhibitors may result in hypothyroidism, indicating a
potential role for VEGF in signaling even in normal
thyroid tissue (30). However, controversial results have
been found related to serum VEGF levels and thyroid
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nodule formation (11–14). These discrepancies may be
explained by the evaluation of a group of patients of mixed
metabolic disease statuses in these studies, complicating
the evaluation of serum VEGF levels, as serum VEGF
levels are induced by insulin and hyperglycemia (4,17). In
our study, patients with and without thyroid nodules had
similar incidences of diabetes, hypertension, angiotensinconverting enzyme inhibitors, angiotensin receptor
blockers, beta blockers, oral antidiabetic drugs, and insulin
use, as well as smoking history. In dyslipidemic patients
with an unfavorable metabolic profile, patients with and
without thyroid nodules had similar VEGF levels. Hence,
after excluding the bias of metabolic profile, serum VEGF
levels did not demonstrate an association with nodule
formation.
The results of several in vivo studies are consistent
with the idea that statins exert antiangiogenic activities,
especially via VEGF-dependent pathways (31,32).
A number of studies demonstrated a reduction in
VEGF levels in patients with dyslipidemia treated with
statins (17,33,34). The dose-dependent effect of statins
on angiogenesis has not been elucidated. Based on
experimental studies, some authors suggested that low
doses of statin may have proangiogenic effects (35).
Statins can promote angiogenesis in ischemic tissue via
the increase of endothelial progenitor cells. However,
studies in diabetic and hypercholesterolemic patients
have demonstrated that low doses also reduce serum
VEGF levels (17,33). VEGF plays a crucial role among
proangiogenic factors. In our study, low-dose statin resulted

in a decrease in VEGF levels in patients without thyroid
nodules, demonstrating the antiangiogenic effect of the
statins. However, in patients with thyroid nodules, statin
treatment did not alter serum VEGF levels, supporting
neither proangiogenic nor antiangiogenic effects of statins
on these patients. The lowering effect of statins on serum
VEGF levels was blunted in patients with thyroid nodules.
Metabolic conditions as well as thyroid nodule presence,
which may also be related to metabolic conditions, seem
to have an influence on serum VEGF levels. The presence
of thyroid nodules may possibly have a subtle influence
on serum VEGF levels where serum VEGF levels are not
altered but fail to respond to exogenous stimuli such as
statin treatment.
In conclusion, 6-month statin treatment decreases
dominant thyroid nodule volume and total nodule
volumes. Although statin treatment decreases serum
VEGF levels in dyslipidemic patients without thyroid
nodules, it has no lowering effect on serum VEGF levels
in patients with thyroid nodules. The decrease in thyroid
nodule volume by statin treatment was associated with
neither metabolic parameters nor serum VEGF levels. Our
results confirm the complex interaction between thyroid
nodule formation and metabolic parameters, as all of our
patients had dyslipidemia, but the ones with nodules failed
to respond to statin treatment with decreasing VEGF
levels. Local expression of VEGF within thyroid tissues
and nodules may be of potential interest in further studies
to elucidate whether VEGF plays a significant role in
statin-associated changes in thyroid/nodule volume.
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